Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106 Outpatient administration was allowed and found to be feasible Currently no FDA-approved CAR-T treatments for WM Data presented at the European Hematology Association 2024 Hybrid Congress WORCESTER, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Mustang Bi ...

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform. The oral presentation includes updat ...

Thicha Satapitanon/iStock via Getty Images Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been able to advance a few CAR-T products in its pipeline. The reason why I believe that it is good to focus on this biotech next is because it is gearing up to report results from two early-stage studies, which could possibly boost shareholder value. The first candidate of which is known as cema-cel [formerly ALLO-501A] that is being advanced for the treatment of patients with relapsed/refractory chronic lymphocyti ...

Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseasesOptimal CAR construct design contributing to an acceptable safety profile, and potential for lasting immune reset are key for treatment adoption Kyverna is currently recruiting for multiple KYSA trials where the company's product candidate KYV-101 is used to treat patients suffering from myasthenia gravis, multiple sclerosis, and lupus nephritisEMERYVILLE, Calif., June 10, 2024 /PRNewswire/ -- Kyv ...

Core Insights - AbelZeta Pharma announced preliminary results from the C-CAR031 study, showing a disease control rate (DCR) of 91.3% and an objective response rate (ORR) of 56.5% in patients with advanced hepatocellular carcinoma (HCC) [1][2][5] Group 1: Study Results - The study reported that 91.3% of patients experienced tumor reductions, with a median reduction of 42.2% [2][5] - The ORR was 75.0% at dose level 4 (DL4) [1][2] - The median overall survival (mOS) was estimated at 11.14 months with a follow-up of 9.03 months [2][5] Group 2: Safety Profile - No dose-limiting toxicity or immune effector cell associated neurotoxicity syndrome (ICANS) was observed [3] - Cytokine release syndrome (CRS) occurred in 91.7% of patients, with the majority being grade 1/2 [3] Group 3: Product Information - C-CAR031 is an autologous, armored GPC3-targeting CAR-T therapy developed for HCC, co-developed by AbelZeta and AstraZeneca [4][6] - The therapy utilizes a novel GPC3-targeting CAR-T designed by AstraZeneca and is manufactured by AbelZeta in China [4][6] Group 4: Company Overview - AbelZeta Pharma is a global clinical-stage biopharmaceutical company focused on innovative cell-based therapeutic products [6] - The company operates in Rockville, Maryland, and Shanghai, China, with a commitment to developing treatments for hematological malignancies and solid tumors [6]

 Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumorsSAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is be ...

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor settingInitial data expected by year-end 2024PHILADELPHIA, May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the first patient was dosed in its Phase 1 clinical trial evaluating CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-mono ...

PARSIPPANY, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ:CAR) (the "Company") announced today that its wholly-owned subsidiary, Avis Budget Finance plc (the "Issuer"), priced a private offering of €200 million aggregate principal amount of additional 7.25% Senior Notes due 2030 (the "Notes"). The Notes will be issued as additional notes under the Indenture, dated as of July 13, 2023, pursuant to which the Issuer previously issued €400 million aggregate principal amount of 7.25% Sen ...

PARSIPPANY, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ:CAR) (the "Company") announced today that its wholly-owned subsidiary, Avis Budget Finance plc (the "Issuer"), intends, subject to market and other customary conditions, to offer €200 million aggregate principal amount of additional 7.25% Senior Notes due 2030 (the "Notes") in a private offering. The Notes will be issued as additional notes under the Indenture, dated as of July 13, 2023, pursuant to which the Issuer previousl ...

Avis Budget Group, Inc. (CAR) reported mixed first-quarter 2024 results, wherein earnings missed the Zacks Consensus Estimate but revenues beat the same.The stock has gained 28.3% since its earnings release on May 1 despite the earnings miss.CAR’s adjusted loss was $3.2 per share compared with the Zacks Consensus Estimate of a loss of $3.15 and year-ago earnings of $7.72. Total revenues of $2.6 billion beat the consensus estimate by a slight margin but decreased marginally year over year.Avis Budget’s share ...